Innocent Ali /Senior Lecturer-Researcher at the University of Dschang, Cameroon

Urgent actions should include development of sustainable capacity for ongoing and future late stage trials. High staff turnover can hamper the mid to longterm development of TB vaccines beyond the early stages. Public engagement, designed and implemented from lessons learnt from implementing other vaccine trials in Sub-Saharan Africa is also important, to prepare and harness public opinion on vaccine impact.